CLEVELAND--(BUSINESS WIRE)--Neuros Medical, Inc., a neuromodulation company, announced today the appointment of Tom Wilder as President and CEO.
Mr. Wilder has over 30 years of experience, having most recently led Sequent Medical, Inc., a neurovascular company that developed the WEB Aneurysm Embolization System, where he served for six years. Sequent was acquired by Terumo Corporation in 2016 for up to $380 million. Prior to joining Sequent, Mr. Wilder was President and CEO of PhotoThera, Inc., a company that was developing a unique therapy for acute ischemic stroke patients. Prior to this, Mr. Wilder served as President and CEO of Micro Therapeutics, Inc. (MTIX), a company also focused on the neurovascular space. MicroTherapeutics was merged into ev3, Inc. (EVVV) in 2006, at a valuation of $360 million. In addition, Mr. Wilder served in positions of increasing responsibility at Medtronic, Inc. (MDT) from 1991 through 2002, most recently as Vice President and General Manager of its endovascular stent grafts division. Mr. Wilder currently serves on the Board of Directors of Penumbra, Inc. (PEN) and Endologix, Inc. (ELGX).
Read More: http://www.businesswire.com/news/home/20170828005030/en/Neuros-Medical-Appoints-Tom-Wilder-President-CEO
Comments are closed.